CIK 0001694665
EVLO Evelo Biosciences, Inc.
Insider trading from SEC Form 4. Last filing Nov 8, 2023. Close $0.00 on Oct 9, 2026, +100% from the 52-week low and -60% from the high.
In brief
Evelo Biosciences, Inc. (EVLO) has 7 SEC Form 4 filings on file from 4 insiders, the latest filed on Nov 8, 2023. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
7 open-market trades have been scored at EVLO. The newest: Mark Bodmer (CSO, President of R&D) sold $1,044 of stock on Nov 8, 2023, filed Nov 8, 2023, scored 5 (weak), under a 10b5-1 plan. The largest of the 7 shown: Mark Bodmer (CSO, President of R&D) sold $2,262 on Nov 2, 2023, scored 5 (weak), under a 10b5-1 plan. 4 insiders sold within 14 days of each other around Nov 8, 2023.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Evelo Biosciences, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 5Weak | Mark Bodmer CSO, President of R&D sell | $1,044 3,163 shares | -11% | - | |
| 2Weak | Marella Thorell Chief Financial Officer sell | $598 1,811 shares | -8% | - | |
| 5Weak | Simba Gill President & CEO sell | $57 172 shares | -1% | - | |
| 0Weak | Duncan McHale Chief Medical Officer sell | $1,024 3,103 shares | -15% | - | |
| 5Weak | Mark Bodmer CSO, President of R&D sell | $2,262 6,854 shares | -24% | - | |
| 7Weak | Marella Thorell Chief Financial Officer sell | $1,320 3,999 shares | -19% | - | |
| 5Weak | Duncan McHale Chief Medical Officer sell | $2,262 6,854 shares | -34% | - |
Transactions
Every row filed, 21 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 7, 2023 | Duncan McHale Chief Medical Officer | MOption exercise Common Stock10b5-1 | +6,500 | - | - | 20,087 | Nov 8, 2023 |
| Nov 7, 2023 | Simba Gill President & CEO | MOption exercise Common Stock10b5-1 | +1,172 | - | - | 17,930 | Nov 8, 2023 |
| Nov 7, 2023 | Marella Thorell Chief Financial Officer | MOption exercise Common Stock10b5-1 | +6,500 | - | - | 24,070 | Nov 8, 2023 |
| Nov 7, 2023 | Mark Bodmer CSO, President of R&D | MOption exercise Common Stock10b5-1 | +6,625 | - | - | 28,895 | Nov 8, 2023 |
| Nov 8, 2023 | Marella Thorell Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -1,811 | $0.33 | $598 | 22,259 | Nov 8, 2023 |
| Nov 8, 2023 | Duncan McHale Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -3,103 | $0.33 | $1,024 | 16,984 | Nov 8, 2023 |
| Nov 8, 2023 | Simba Gill President & CEO | SOpen-market sale Common Stock10b5-1 | -172 | $0.33 | $57 | 17,758 | Nov 8, 2023 |
| Nov 8, 2023 | Mark Bodmer CSO, President of R&D | SOpen-market sale Common Stock10b5-1 | -3,163 | $0.33 | $1,044 | 25,732 | Nov 8, 2023 |
| Nov 7, 2023 | Mark Bodmer CSO, President of R&D | MOption exercise Restricted Stock Unitsderivative10b5-1 | -6,625 | $0.00 | $0 | 6,625 | Nov 8, 2023 |
| Nov 7, 2023 | Marella Thorell Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative10b5-1 | -6,500 | $0.00 | $0 | 6,500 | Nov 8, 2023 |
| Nov 7, 2023 | Simba Gill President & CEO | MOption exercise Restricted Stock Unitsderivative10b5-1 | -1,172 | $0.00 | $0 | 15,236 | Nov 8, 2023 |
| Nov 7, 2023 | Duncan McHale Chief Medical Officer | MOption exercise Restricted Stock Unitsderivative10b5-1 | -6,500 | $0.00 | $0 | 6,500 | Nov 8, 2023 |
| Nov 1, 2023 | Mark Bodmer CSO, President of R&D | MOption exercise Common Stock10b5-1 | +12,500 | - | - | 29,124 | Nov 3, 2023 |
| Nov 1, 2023 | Marella Thorell Chief Financial Officer | MOption exercise Common Stock10b5-1 | +12,500 | - | - | 21,569 | Nov 3, 2023 |
| Nov 1, 2023 | Duncan McHale Chief Medical Officer | MOption exercise Common Stock10b5-1 | +12,500 | - | - | 20,441 | Nov 3, 2023 |
| Nov 2, 2023 | Mark Bodmer CSO, President of R&D | SOpen-market sale Common Stock10b5-1 | -6,854 | $0.33 | $2,262 | 22,270 | Nov 3, 2023 |
| Nov 2, 2023 | Marella Thorell Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -3,999 | $0.33 | $1,320 | 17,570 | Nov 3, 2023 |
| Nov 2, 2023 | Duncan McHale Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -6,854 | $0.33 | $2,262 | 13,587 | Nov 3, 2023 |
| Nov 1, 2023 | Mark Bodmer CSO, President of R&D | MOption exercise Restricted Stock Unitsderivative10b5-1 | -12,500 | $0.00 | $0 | 25,000 | Nov 3, 2023 |
| Nov 1, 2023 | Marella Thorell Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative10b5-1 | -12,500 | $0.00 | $0 | 25,000 | Nov 3, 2023 |
| Nov 1, 2023 | Duncan McHale Chief Medical Officer | MOption exercise Restricted Stock Unitsderivative10b5-1 | -12,500 | $0.00 | $0 | 25,000 | Nov 3, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Mark BodmerCSO, President of R&D
- Simba GillPresident & CEO
- Duncan McHaleChief Medical Officer
- Marella ThorellChief Financial Officer
Questions about EVLO
Answered from the filings on this page, as of the latest one.
Are insiders buying EVLO?
No. In the last 90 days no insider at Evelo Biosciences, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade EVLO on the open market?
Mark Bodmer (CSO, President of R&D) sold $1,044 of EVLO on Nov 8, 2023 and filed the Form 4 on Nov 8, 2023. InsiderTell scored 5 (weak), under a 10b5-1 plan, with 4 insiders on the same side within 14 days.
How many insiders file Form 4 at Evelo Biosciences, Inc.?
4 people have filed a Form 4 at Evelo Biosciences, Inc., among them Mark Bodmer (CSO, President of R&D), Simba Gill (President & CEO), Duncan McHale (Chief Medical Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.